0 32

Cited 0 times in

Cefepime Versus Cefepime Plus Amikacin as an Initial Antibiotic Choice for Pediatric Cancer Patients With Febrile Neutropenia in an Era of Increasing Cefepime Resistance

Authors
 Na Hee Lee  ;  Ji-Man Kang  ;  Ji Won Lee  ;  Hee Jae Huh  ;  Nam Yong Lee  ;  Keon Hee Yoo  ;  Ki Woong Sung  ;  Hong Hoe Koo  ;  Yae-Jean Kim 
Citation
 PEDIATRIC INFECTIOUS DISEASE JOURNAL, Vol.39(10) : 931-936, 2020-10 
Journal Title
 PEDIATRIC INFECTIOUS DISEASE JOURNAL 
ISSN
 0891-3668 
Issue Date
2020-10
Abstract
Background: We investigated the treatment outcomes before and after the addition of amikacin to cefepime monotherapy as an initial empirical antibiotic treatment in pediatric cancer patients with febrile neutropenia. Methods: This was a retrospective historical cohort study. The subjects were pediatric cancer patients who visited the emergency room at the Samsung Medical Center, Seoul, Korea, due to chemotherapy-induced febrile neutropenia, between January 2011 and December 2016. Since September 2014, the empirical antimicrobial treatment regimen for febrile neutropenia was changed from high-dose cefepime monotherapy to combination therapy of adding a single dose of amikacin. Results: Two hundred twenty-five bacteremia episodes in 164 patients were reported during the study period. Bacteremia caused by cefepime-resistant Gram-negative bacteria was observed in 16% of patients before September 2014 and in 21% of the patients after September 2014 (P = 0.331). Use of appropriate empirical antibiotic treatments increased from 62% to 83% following addition of amikacin to cefepime treatment (P = 0.003). The duration of fever was shorter in the cefepime plus amikacin group than in the cefepime group (22 vs. 34 hours, P = 0.014); however, rates of septic shock and pediatric intensive care unit hospitalizations were not significantly different between the 2 groups (septic shock, both 7%, P = 0.436; pediatric intensive care unit 3% vs. 1%, P = 0.647). Conclusions: We observed no additional benefit of amikacin addition to high-dose cefepime monotherapy. Therefore, adding amikacin to cefepime monotherapy in conditions where cefepime-resistant Gram-negative bacteremia amounts to 20% or less may not be justified.
Full Text
https://journals.lww.com/pidj/Fulltext/2020/10000/Cefepime_Versus_Cefepime_Plus_Amikacin_as_an.14.aspx
DOI
10.1097/INF.0000000000002751
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Pediatrics (소아과학교실) > 1. Journal Papers
Yonsei Authors
Kang, Ji-Man(강지만) ORCID logo https://orcid.org/0000-0002-0678-4964
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/180503
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links